Evidence map›Paper›PMID 20544245›Full record

Trial reportClinical rheumatology2011

A long-term prospective randomized controlled study of non-specific interstitial pneumonia (NSIP) treatment in scleroderma.

Diogo S Domiciano, Eloisa Bonfá, Claudia T L Borges, Ronaldo A Kairalla, Vera L Capelozzi, Edwin Parra, Romy Beatriz Christmann

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Clinical rheumatology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 8 pooled it
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 8 syntheses or guidelines pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Guideline
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Assessment of skin involvement in systemic sclerosis.Rheumatology (Oxford, England) · 2017
    Pooled it
  8. Pooled it
  9. Trial
  10. Review
  11. Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence.European respiratory review : an official journal of the European Respiratory Society · 2018
    Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Recent Treatments of Interstitial Lung Disease with Systemic Sclerosis.Clinical medicine insights. Circulatory, respiratory and pulmonary medicine · 2015
    Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Diogo S DomicianoDivision of Rheumatology, University of São Paulo, São Paulo, Brazil.
Eloisa Bonfá
Claudia T L Borges
Ronaldo A Kairalla
Vera L Capelozzi
Edwin Parra
Romy Beatriz Christmann
Universidade de São Paulo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledThe association of cyclophosphamide (CYC) and prednisone (PRED) for the treatment of lung fibrosis in systemic sclerosis (SSc) was only evaluated in uncontrolled studies, although in idiopathic interstitial lung disease (ILD) this association seems to be beneficial in patients with non-specific interstitial pneumonia (NSIP).

objectivesTo treat SSc-ILD in a prospective open-label controlled study based on lung pattern during 12 months of treatment.

methodsA 3-year analysis was also performed. Twenty-four consecutive patients with SSc and ILD were submitted to an open lung biopsy. Eighteen patients (NSIP) were randomized in two groups: CYC versus CYC + PRED during 12 months. Lung function tests (diffusion lung capacity of monoxide carbone corrected for hemoglobin concentration (DLCO-Hb), forced vital capacity (FVC), total lung capacity) and Modified Rodnan Skin Score (MRSS) were performed before, after one of treatment and after 3 years from the end of the treatment.

resultsPulmonary function tests were similar in both groups on baseline. After 1 year of treatment, FVC% was comparable between CYC groups (p = 0.72) and in CYC + PRED (p = 0.40). Three years after the end of treatment, FVC% values (p = 0.39 in group CYC and p = 0.61 in CYC + PRED and p = 0.22 in CYC + PRED) and DLCO-Hb (p = 0.54 in CYC and p = 0.28 in CYC + PRED) were similar compared to 1 year of treatment. We observed a reduction of the MRSS in the CYC + PRED group after 1 year of treatment (p = 0.02); although after 3 years, MRSS values remained stable in both groups.

conclusionsCYC was effective to stabilize lung function parameters in NSIP lung pattern of SSc disease for 3 years after the end of a 1-year therapy.

Indexed as

AdultCyclophosphamideDrug Therapy, CombinationFemaleHumansImmunosuppressive AgentsLung Diseases, InterstitialMiddle AgedPrednisoneProspective StudiesRespiratory Function TestsScleroderma, SystemicTreatment OutcomeCyclophosphamideImmunosuppressive AgentsPrednisone

Identifiers

PMID20544245
OpenAlexW1991249147

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.